CTMX (CytomX Therapeutics) Float Percentage Of Total Shares Outstanding: 88.13% (As of Jun. 27, 2026)


CTMX CytomX Therapeutics Inc CTMX
36 GF Score
Price $3.38
GF Value $0.28
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CytomX Therapeutics Float Percentage Of Total Shares Outstanding?

CytomX Therapeutics CTMX +3.66% 36 Float Percentage Of Total Shares Outstanding is 88.13% as of Jun. 27, 2026. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CytomX Therapeutics's float shares is 191.86 Mil. CytomX Therapeutics's total shares outstanding is 217.70 Mil. CytomX Therapeutics's float percentage of total shares outstanding is 88.13%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CytomX Therapeutics's Insider Ownership is 1.22%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CytomX Therapeutics's Institutional Ownership is 92.96%.

CTMX
36GF Score
CytomX Therapeutics Inc CTMX
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytomX Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

CytomX Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=191.86/217.70
=88.13%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 88.13% mean?
CytomX Therapeutics (CTMX) has a Float Percentage Of Total Shares Outstanding of 88.13% as of Jun. 27, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on CytomX Therapeutics and its competitors.
Is CytomX Therapeutics' Float Percentage Of Total Shares Outstanding too high?
CytomX Therapeutics' current Float Percentage Of Total Shares Outstanding is 88.13%. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Float Percentage Of Total Shares Outstanding compare to SMNR and AURA?
CytomX Therapeutics' Float Percentage Of Total Shares Outstanding of 88.13% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on CytomX Therapeutics and its competitors. CytomX Therapeutics's current Float Percentage Of Total Shares Outstanding is 88.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.38 — trading 1107.1% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 88.13%. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Float Percentage Of Total Shares Outstanding is 88.13% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytomX Therapeutics (CTMX) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of $3.38 is trading 1107.1% above its estimated GF Value™ of $0.28. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for CTMX:

  • Float Percentage Of Total Shares Outstanding: 88.13%
  • GF Value™: $0.28 vs. price of $3.38 (1107.1% above fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CytomX Therapeutics Business Description

Other Exchanges 6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score

Get the complete analysis for CTMX

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.38
Price
$0.28
GF Value